Midazolam
Borderline Personality Disorder
Joshua RosenblatSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Borderline Personality Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Selegiline Mood and Anxiety Research, Inc | Phase 3 | BB |
LITHIUM, ELEMENTAL Columbia Northwest Pharmaceuticals | Phase 2 | B |
Teonanacatl University of Chicago | Phase 2 | B |
CITALOPRAM Columbia Northwest Pharmaceuticals | Phase 2 | B |
Escitalopram University of Chicago | Phase 2 | CCC |
View all 9 →
Same molecule, other indications
Midazolam is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →